A 52-year-old woman intermittently ingested 3 g of "Tusanqi powder" one to two times a day. Fatigue, abdominal distension, and abdominal pain occurred after 15 days of using the drug. Her blood coagulation indices were as follows: PT: 15.0 s, PTA: 83%, and INR: 1.07. Biochemical test results were as follows: TBIL: 45.9 micromol/L, DBIL: 30.4 micromol/L, ALB: 31.0 g/L, ALT: 1142 U/L, AST: 1076 U/L, ALP: 118 U/L, and GGT: 296 U/L. Liver ultrasonography showed diffuse enlargement, liver parenchyma echogenicity with increased coarse density, uneven distribution, and visible "patch-like" areas of reduced echogenicity along the hepatic veins. A small amount of peritoneal effusion was also present. A CT scan showed an uneven reduction in liver parenchyma density, a characteristic "map-like" appearance of the liver parenchyma during the arterial and venous phases with uneven enhancement, and thin and unclear hepatic veins. Enlarged lymph nodes in the porta hepatis were also observed. After HSOS was diagnosed, treatment with low-molecular-weight heparin was initiated. After 30 days of treatment, the symptoms of the patient improved, and her biochemical indices and CT findings were close to normal (Figure 4a and b). The patient was readmitted for abnormal liver function in the 8th month of the disease and underwent a liver biopsy. Pathological features included mild inflammation in the central area, obvious dilatation of the hepatic sinus, mild fibrosis around the sinus, fibrosis deposition in the sinus, and an embolism in the central vein. Anticoagulant therapy with rivaroxaban tablets was then initiated for the patient (Figure 4c and d).